Compelling Returns From
Funding Global Cannabinoid R&D

Financing the discovery of brand new plant-based drugs that could help
improve the lives of many people around the world.

US$16.5 billion

Global medical cannabis market was
worth US$16.5 billion in 2019¹

22.8% Growth

22.8% compound annual growth rate (CAGR) forecast over the 2020-25 period¹

$58.5 billion

Market forecast to be worth US$58.5
billion by 2025¹

About Cannadex

Financing the discovery of brand new plant-based

drugs that could help improve the lives of many
people around the world.

Funding R&D companies to research the pharmacology of cannabinoids which continues to yield highly promising data and new IP across a range of therapeutic areas

Backing global-leading cannabinoid scientists which continue to explore the potential of a range of novel cannabinoid molecules in a number of distinct therapeutic areas including epilepsy, glioma, and schizophrenia

Managed by a team of proven entrepreneurs and businessmen that have a good understanding of this market

The History of
Medicinal Cannabis

Medical cannabis is any cannabis-based medicine that relieves symptoms.
Cannabis has been used medicinally for more than 4,500 years.

In 2,727BC, Emperor Shen-Nung recognised its treatment properties in over 100 ailments including rheumatism and gout. Napoleon returned from Egypt in 1798 with cannabis which was investigated for pain relief and sedation. Elsewhere at that time, cannabis was being used to treat tumours, coughs and jaundice.

In the early 20th century cannabis use fell out of favour with
regulators and the culture of the western world.

Medical cannabis
becomes legalised

Public opinion has firmly swung in favour of medical
cannabis which has put pressure on many governments
to legalise medical cannabis treatment

Trend led by Canada which changed it laws in 2001 to legalise the medicinal use of cannabis

Growing number of countries legalising cannabis for medical use

UK regulations changed in November 2018 following public pressure

Today the NHS prescribes medicinal cannabis for severe forms of epilepsy, nausea caused by chemotherapy and muscle stiffness/ spasms caused by MS

Medical cannabis is still in its introductory phase in the healthcare industry

Substantial growth is predicted for medical cannabis

Peer Group Comparisons

Public opinion has firmly swung in favour of medical cannabis which has put
pressure on many governments to legalise medical cannabis treatment

Company Share price2 Market capitalisation Enterprise value Comments
Canopy Growth
(TSE:WEED)
C$18.73 £3,760m £3,000m First publicly-traded Canadian CBD company, and the first cannabis-producer to be listed on the NYSE in 2018. Multiple subsidiary companies and brands, including Tweed and Spectrum Therapeutics; with a product line the includes oils, concentrates, soft gel capsules and hemp.
GW
Pharmaceuticals
(NMQ:GWPH)
US$81.80 £2,060m £1,590m Global leader in developing cannabinoid-based medicines. Its Epidolex was the first FDA-approved medicine derived from cannabis plant, which it is focusing on turning into a block buster drug.
Aurora Cannabis
(TSE:ACB)
C$1.13 £758m £988m Product line includes CBD oil, soft gels, and milled blends. Their CBD products are sold on a prescription, medical basis for Canadian markets.
Tilray
(NSQ:TLRY)
US$5.54 £497m £780m First GMP-certified medical cannabis producer of cannabis flower and extract products; with its CBD products distributed to doctors, hospitals, governments, and researchers in five continents.
Charlotte’s Web
(TSE:CWEB)
C$5.68 £344m £316m Charlotte’s Web has a unique formula to other CBD products, with a high amount of cannabidiol and low THC. Product lines includes CBD oil, gummies and capsules, as well as CBD dog products.
Medical
Marijuana
(OTC:MJNA)
US$0.015 £44m £50m Medical Marijuana developed the first legal supply of CBD and first publicly traded CBD company in the US. Has 8 brands of CBD products including CBD oils, hemp foods, clothing & baby products.
CV Sciences
(OTC:CVSI)
US$0.64 £52m £44m Focuses on pharmaceutical and consumer markets. Developing cannabidiol-based medicine pending FDA approval. Sells various botanical-based CBD consumer products in health food stores.
Elixinol Global
(ASX:EXL)
A$0.275 £18m £10m Wholesale CBD supplier of products such as oil capsules, tinctures, liposomes, topicals, and hemp seeds. Sold through dispensaries, shops, health stores, and through healthcare professionals.
Isodiol
International
(CBSX:ISOL)
C$0.085 £2.8m £5.3m Isodiolis a manufacturer of natural, non-GMO, THC-free cannabinoid products. Products include mainstream CBD products such as capsules, oral sprays, topicals, and oils. Sells its products in bulk material, private label, and wholesale options
Gaia Grow
(CVE:GAIA)
C$0.03 £3.4m £1.9m Committed to creating sustainable and clean products has an extensive product line of natural remedies and supplements including hemp extract oils.

Rapidly growing market

Quickly being legalised in growing number of countries: Argentina, Brazil, Canada,
Chile, Colombia, Czech, Germany, Italy, Mexico, Spain, UK, USA and Uruguay.

US$16.5 billion

Global medical cannabis market was
worth US$16.5 billion in 2019¹

22.8% Growth

22.8% compound annual growth rate (CAGR) forecast over the 2020-25 period¹

$58.5 billion

Market forecast to be worth
US$58.5 billion by 2025¹

Global CBD Market Growing even faster¹

More rapid growth is forecast for this sub-sector of the medical cannabis

US$553.7 million

Global CBD market valued at
US$553.7 million in 2020

33.5% Growth

by the end of 2026 growing at a CAGR
of 33.5% during 2021-26²

$4,268.3 million

forecast to reach US$4,268.3 million
by the end of 2026

CBD wellness is an expanding category with CBD incorporated into edibles as well as being infused
into cosmetics and pet products. Industry clamouring for CBD to listed as “generally recognised as
safe” and so it is classified in the same way as vanilla flavouring and caffeine.

Global players entering the CBD market

Multinational drinks brands have set their sights on developing cannabis based drinks. Owner of
Corona beer, Constellation brands, invested US$4 billion into the cannabis group Canopy Growth
in 2018. Coca-Cola is thought to have been in talks with Aurora Cannabis to create a CBD drink.
Speculation that Starbucks is becoming involved in this market.

Our Business Process

In-depth market research to identify potential investee companies with compelling R&D in medical cannabis

Extensive face to face meetings with potential investee companies

Due diligence and painstaking analysis of technology and business model

Advance funds as direct investment or loans against achieving pre-agreed milestones

Work with management teams to create value

Appointment of key advisers and able to nominate a Non-Executive Director to the board

Exits will be sought by way of share buy-back, listing on a recognised stock exchange, acquisition by an industrial buyer, merger with another organisation etc.

Contact us

Enter your details to get in touch

Your Name
Email address

Phone number

Subject
Message

Blackwell House
Guildhall Yard
London
EC2V 5AE

Tel: 020 3633 9145
Email: info@cannadex.com